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RESEARCH ARTICLE Open Access
Prognostic value of microvessel density in
stage II and III colon cancer patients: a
retrospective cohort study
Sjoerd H. den Uil1,8, Evert van den Broek2,8, Veerle M. H. Coupé3, Thomas T. Vellinga4, Pien M. Delis-van Diemen5,
Herman Bril6, Eric J. Th. Belt7, Onno Kranenburg4, Hein B. A. C. Stockmann1, Jeroen A. M. Belien8,
Gerrit A. Meijer5 and Remond J. A. Fijneman5*
Abstract
Background: Microvessel density (MVD), as a derived marker for angiogenesis, has been associated with poor
outcome in several types of cancer. This study aimed to evaluate the prognostic value of MVD in stage II and III
colon cancer and its relation to tumour-stroma-percentage (TSP) and expression of HIF1A and VEGFA.
Methods: Formalin-fixed paraffin-embedded (FFPE) colon cancer tissues were collected from 53 stage II and 54
(5-fluorouracil-treated) stage III patients. MVD was scored by digital morphometric analysis of CD31-stained whole
tumour sections. TSP was scored using haematoxylin-eosin stained slides. Protein expression of HIF1A and VEGFA
was determined by immunohistochemical evaluation of tissue microarrays.
Results: Median MVD was higher in stage III compared to stage II colon cancers (11.1% versus 5.6% CD31-
positive tissue area, p < 0.001). High MVD in stage II patients tended to be associated with poor disease
free survival (DFS) in univariate analysis (p = 0.056). In contrast, high MVD in 5FU-treated stage III patients
was associated with better DFS (p = 0.006). Prognostic value for MVD was observed in multivariate analyses
for both cancer stages.
Conclusions: MVD is an independent prognostic factor associated with poor DFS in stage II colon cancer
patients, and with better DFS in stage III colon cancer patients treated with adjuvant chemotherapy.
Keywords: Colon cancer, Microvessel density, Angiogenesis, Prognosis
Background
The physiological role of angiogenesis at adult age is
confined to wound- and bone healing and the female re-
productive cycle, and therefore is activated temporarily.
In contrast, the angiogenic pathway is often constitu-
tively activated in tumours to meet their needs for nutri-
ents and to facilitate tumour growth and metastasis.
This is an early event in the development of cancer and
can already be observed in pre-malignant lesions [1–3].
However, these newly formed blood vessels have a less
distinct organized hierarchy [4], and are prone to vascu-
lar leakage for their irregular endothelial layer with
intermediate spaces [5]. Interstitial blood pressure is
increased leading to compromised blood flow and thus
hypoxia and acidosis [6, 7]. Expression of the alpha sub-
unit of hypoxia-inducible factor 1 (HIF1A) is stabilized as
a result of this hypoxia and evokes angiogenesis by the
upregulation of expression of vascular endothelial growth
factor A (VEGFA) [8, 9]. This process is enhanced by the
influence of for instance tumour associated macrophages,
cancer-associated fibroblasts, and the extracellular matrix
[10]. Constitutive upregulation of HIF1A and VEGFA
expression can also be induced by oncogene signalling,
e.g. by transforming growth factor-β (TFG-β), the involve-
ment of the Wnt/β-catenin pathway and inhibition by the
p53 pathway [11–16]. HIF1a is furthermore known to
interact with apoptotic markers like Bax and Bcl-xL [17].
It leads to enhanced proliferation, survival and migration
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of endothelial cells, increased vascular permeability and al-
tered gene expression [14, 18, 19].
Desmoplastic tumour stroma interacts with and supports
the tumour parenchyma, forming a microenvironment in
which the tumour can progress. The tumour stroma and
the microenvironment promote angiogenesis and tumour
progression and eventually metastasis [10, 20]. There is
increasing evidence that the proportion of this stroma in
colon cancer is inversely related to survival [21, 22]. Conse-
quently, tumours with high tumour-stroma percentage
(TSP) are likely to express more angiogenic factors, leading
to more angiogenesis, and angiogenesis-rich tumours may
be associated with a worse prognosis.
In contrast to stroma percentage, there is no direct meas-
ure or single marker for angiogenesis to which survival can
be correlated [21]. Microvessel density (MVD) has been
analysed since the early 90’s as an angiogenesis-derived
marker [23, 24]. The hypothesis that high-MVD tumours
are associated with poor prognosis was indeed proven in
breast cancer, where higher MVD was associated with poor
survival [25, 26], and in non-small cell lung cancer where
high MVD was associated with poor survival after surgery
[27]. In colorectal cancer (CRC), prognostic value of MVD
has remained inconclusive, although some publications
suggest associations with survival [28–33].
The aim of this study was to examine the relation of
MVD to disease-recurrence, in both stage II and stage
III colon cancer patients, while taking into account the
amount of tumour stroma (TSP) and expression of
HIF1A and VEGFA.
Materials and methods
Study design and population
Based on a previously established well-documented
retrospective cohort of 386 stage II and III colon cancer
patients with no prior history of CRC [34], we here
selected a subset of 53 stage II and 54 stage III colon
cancer patients of whom whole tissue sections were
available for MVD analysis. In this subset all stage III
patients were treated with adjuvant 5-FU based chemo-
therapy, whilst all stage II patients were treated with
surgical resection only. The tumours from these patients
were microsatellite stable (MSS), as previously deter-
mined by PCR analysis [34]. Clinical data and tumour
tissue was obtained conform the “Code for Proper Sec-
ondary Use of Human Tissue in The Netherlands” [35].
Baseline characteristics and clinicopathological data are
shown in Additional file 2: Table S1.
CD31 immunohistochemistry and microvessel density
analysis
Four micrometer FFPE whole tissue sections were
mounted on glass slides, deparaffinised and rehydrated.
To identify (micro) vessels, sections were stained with a
mouse monoclonal antibody directed against CD31 (anti
human CD31, clone JC70A, catalogue number M0823,
Dako, Heverlee, Belgium) in a 1/50 solution and using a
Tris (pH 9) buffer for maximum retrieval in a microwave
for 1 h. A Powervision+ method (Immunologic, Duiven,
The Netherlands) was used as secondary antigens, after
1 h incubation at room temperature. These sections
were digitized using a Mirax slide scanner system
equipped with a 20x objective with a numerical aperture
of 0,75 (3DHISTECH, Budapest, Hungary) and a Sony
DFW-X710 Fire Wire 1/3″ type progressive SCAN IT
CCD (pixel size 4,65 × 4,65 μm2) resulting in an actual
scan resolution at 20x of 0,23 μm. Monitors used for
selection and scoring were calibrated using Spyder2PRO
software (v.1.0–16; Panone Colorvision, Regensdorf,
Switzerland). Representative tumour tissue was delin-
eated using Pannoramic Viewer (v 1.15.3, 3DHISTECH
Ltd), and damaged parts and/or absence of tissue in
delineated tumours were annotated as well, and later
digitally excluded for analysis. A pathologist (HB)
approved the delineating process. The delineated areas
were exported as high resolution TIFF-files. This re-
sulted in TIFF files of 60 to 320Mb with a minimum
resolution of approximately 2500 × 3100 pixels, depend-
ing on the original tumour size. A Java-based image
processing program, ImageJ (v1.47, Wayne Rasband,
64bits), was used to import the TIFF files and to perform
morphometric image analysis to detect and measure the
microvessels. This full script, is a CD31-specific version
of previously published work [36], see Additional file 1.
In brief, this script analyses all stained pixels in included
tissue in the delineated TIFF-files. Based on RGB colour
codes, the CD31 positive cells were identified. The
brown (clustered) pixels represented endothelial cells,
whereas the non-brown pixel represented normal
stroma, epithelial cells etc. A size-threshold of minimal
hundred CD31-positive pixels was used as minimal size
of microvessels. The total percentage of CD31-positive
(clustered) pixels per tissue area analysed is used as
measure for the average microvessel density in that
whole tumour section.
Tumour-stroma percentage
For TSP analysis, 4 μm FFPE tissue sections were
mounted on glass slides, deparaffinised and rehydrated,
and stained with haematoxylin-eosin (HE). Neoplastic
epithelium and stroma was quantified using QProdit
(Leica) stereology software. The borders of the tumour
in each section were annotated. Subsequently, the soft-
ware generated a 400-point grid for a 20x objective
within these borders. At each point, the tissue was
scored for epithelium or stroma. Tumour-stroma per-
centage was calculated using the number of stromal hits
divided by the total number of both epithelial and
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stromal hits. Since some sections were damaged, 99
patients remained for analysis.
HIF1A and VEGFA immunohistochemistry and TMA
analysis
Tissue micro arrays (TMA) were generated from these
patients as described previously [37]. Expression of
HIF1A and VEGFA was determined by immunohisto-
chemical evaluation of TMAs, using previously estab-
lished workflows [37]. For HIF1A, antigen retrieval was
performed in antigen retrieval solution (DAKO,
Glostrup, Denmark) for 45 min at 96 °C. Then, the pri-
mary antibody against HIF1A (mouse monoclonal, clone
54, catalogue number 610958, BD, Franklin Lakes, USA)
was incubated for 30 min with a 1/500 dilution at room
temperature. The amplification reagent from the Catala-
zyd Signal Amplification system (CSA, Dako kit) was
used for detection of the staining. For VEGFA expres-
sion (mouse monoclonal, clone VG1, catalogue number
MS-1467-P1, Neomarkers, Fermont, USA) a Tris (pH 9)
buffer in the microwave was used for antigen retrieval,
with subsequent incubation for 1 h and secondary
visualization also by a Powervision+ method.
Protein expression analysis of TMAs was performed as
described previously [37]. In brief, six cores per patient
were examined and scored blindly for intensity (negative,
weak, moderate and strong) of stained cells, using dedi-
cated TMA scoring software (Pannoramic Viewer,
v1.15.5; 3DHISTECH Ltd). Scores were internally cor-
rected for stromal- and background staining. Damaged
and missing cores were not scored. Expression was
scored in cytoplasm of epithelial cells. Scores were
obtained for 103 (HIF1A) and 100 (VEGFA) patients, re-
spectively. For further statistical analyses, all scores were
converted to dichotomous values using ROC-based
cross-validation analysis [37].
Statistical analysis
Kolmogorov-Smirnov (KS) test was used to assess the
normality of the distribution of MVD- and TSP-values.
For analysis of differences in clinical and histological
baseline parameters between study groups (stage and
MVD) independent-t-testing, Mann-Whitney U and chi-
square tests were used. In both stage II and III, continu-
ous MVD- and stromal data was dichotomized for
further (survival) analysis, based on highest specificity
and sensitivity in ROC-analysis. This resulted in high-
MVD when MVD was higher than 5.45% for stage II,
and higher than 8.91% for stage III colon cancer. Stroma
was subsequently defined as high if TSP > 43,1% for
stage II, and TSP > 49,2% for stage III colon cancer. Dif-
ference in disease free survival (DFS) was visualised with
Kaplan Meier curves and log-rank. Hazard ratio’s (HR)
and 95% confidence interval (95% CI) were estimated
with cox-regression analysis. Multivariate analysis was
performed using stepwise backwards Cox regression,
with DFS as dependent variable (p-out = 0.1). Similar
statistics were performed on expression scores of HIF1A
and VEGFA. Associations between MVD, TSP, HIF1A
and VEGFA were analysed with chi-square tests and
spearman’s rho-test. All statistical analyses were proc-
essed in SPSS (IBM SPSS Statistics for windows, SPSS
Inc., Chicago, Illinois, USA), with two-sided analysis and
a significance level of p < 0.05.
Results
MVD in stage II and stage III colon cancer
For determining MVD, whole tissue sections were
stained with CD31 (Fig. 1a). Baseline clinical and
pathological data characteristics of the cohort are pre-
sented in Additional file 2: Table S1, stratified for
stage II and III colon cancer. Besides differences that
are inherent to a comparison of stage II to stage III
patients (adjuvant chemotherapy, T- and N-stadium),
stage III patients were significantly younger (65,5 ver-
sus 72.7 years; p = 0.004) and had significantly more
angioinvasion, defined by the observation of epithelial
cells within the (lymph) vascular lumen (38.9% versus
11.3%, p = 0.001).
Mean MVD of 107 tumours was 10.4%, with a median
of 9.0. In stage III tumours, MVD was significantly
higher compared to stage II (11.1 and 5.6%, respectively;
p < 0.001, Fig. 2a). Within stage II, no differences were
seen in clinicopathological characteristics between
MVD-high and –low group. In stage III tumours, only
more ulceration (p = 0.042) and less recurrences in high-
MVD patients (p = 0.013) were observed. Clinicopatho-
logical characteristics for high versus low MVD, within
both stages, are presented in Table 1.
High MVD is associated with poor DFS in stage II, and
better DFS in adjuvant treated stage III colon cancers
To investigate the univariate association of MVD with
survival in stage II patients, DFS was analysed and
visualized using Kaplan Meier curves. For stage II,
high MVD tended to be associated with worse DFS
(HR 2.53; 95% CI 0.95–6.76; Log-rank p = 0.056,
Fig. 3a). Similarly, the univariate effect of MVD on
DFS in stage III was investigated. In contrast to the
association in stage II, high MVD is associated with
better DFS in stage III patients, all treated with adju-
vant chemotherapy (HR 0.34; 95% CI 0.16–0.76; Log-
rank p = 0.006, Fig. 3b).
No association between DFS and TSP, HIF1A or VEGFA
Examples of expression of HIF1A and VEGFA are
shown in Fig. 1b, and results and survival curves for
TSP, HIF1A and VEGFA are presented in
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A B
Fig. 2 Comparison between stage II and stage III colon cancer patients for a microvessel density; and b tumour-stroma percentage. P values
were obtained by Mann-Whitney U analysis
A
B
Fig. 1 Examples of immunohistochemical stainings for a: CD31 on whole tissue section; and b: HIF1A and VEGFA on TMA cores, scored as
negative, weak, moderate, strong
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Additional file 3: Figure S1-S3. In contrast to MVD, TSP
was not significantly different between stage II and III
colon cancers (p = 0.062, Fig. 2b). More stroma showed
a trend of being related to poor DFS in stage II (HR
2.07; 95% CI 0.76–5.60; Log-rank p = 0.144, Additional
file 3: Figure S1a). Also for expression of HIF1A and
VEGFA, no statistically significant associations were
observed (Additional file 3: Figure S2-S3).
Microvessel density is an independent prognostic factor
in stage II and III colon cancer patients
A multivariate model for 5-year DFS was built using
stepwise backward Cox-regression. MVD, TSP, HIF1A,
VEGFA, right-sided, diameter, degree of differentiation,
ulceration and angioinvasion were included for analysis.
In both stage II and stage III colon cancer, MVD was
retained in the model significantly, demonstrating its
Table 1 Clinicopathological characteristics
Stage II:
n = 53 (%)
Stage III:
n = 54 (%)
MVD-low n = 26 (%) MVD-high n = 27 (%) P-value MVD-low n = 15 (%) MVD-high n = 39 (%) P-value
Sex
Male 14 (53.8) 14 (51.8) 10 (66.7) 25 (64.1)
Female 12 (46.2) 13 (48.2) 0.88 5 (33.3) 14 (35.9) 0.86
Age, mean (s.d.) in years 73.7 (11.3) 70.9 (13.3) 0.41 63.6 (9.8) 66.6 (10.1) 0.32
Right sided tumour 9 (34.6) 8 (29.6) 0.70 7 (46.7) 18 (46.2) 0.97
Tumour diameter, mean (s.d.) in mm 39.2 (20.7) 40.80 (19.3) 0.61 36.4 (10.5) 33.9 (13.4) 0.44
Histological grade
Good 2 (7.7) 3 (11.1) 1 (6.7) 1 (2.6)
Average 23 (88.5) 23 (85.2) 12 (80.0) 35 (89.7)
Poor 1 (3.8) 1 (3.7) 0.91 2 (13.3) 3 (7.7) 0.61
Tumour stage
T1 – – 1 (2.6)
T2 – 1 (6.7) 6 (15.4)
T3 23 (88.5) 26 (96.3) 10 (66.7) 30 (76.9)
T4 3 (11.5) 1 (3.7) 0.28 4 (26.7) 2 (5.1) 0.13
Nodal stage (stage III)
N1 – – 12 (80.0) 22 (56.4)
N2 – – – 3 (20.0) 17 (43.6) 0.11
Mucinous differentiation. 8 (30.8) 4 (14.8) 0.17 1 (6.7) 4 (10.3) 0.68
Ulceration 18 (69.2) 23 (85.2) 0.17 10 (66.7) 35 (89.7) 0.042*
Angioinvasion 2 (7.7) 4 (14.8) 0.41 7 (46.7) 14 (35.9) 0.47
Perforation
No 24 (92.3) 24 (88.9) 14 (93.3) 37 (94.9)
Before surgery 1 (3.8) 1 (3.7) 1 (6.7) 1 (2.6)
During surgery – 1 (3.7) – –
After surgery 1 (3.8) 1 (3.7) 0.81 – 1 (2.6) 0.64
Tumour spill 1 (3.8) 2 (7.4) 0.58 1 (6.7) – 0.10
Adjuvant chemo 0 0 – 15 (100.0) 39 (100.0) –
Recurrence 6 (23.1) 12 (44.4) 0.10 11 (73.3) 14 (35.9) 0.013*
CRC mortality 6 (23.1) 9 (33.3) 0.41 8 (53.3) 12 (30.8) 0.12
Overall mortality 14 (53.8) 16 (59.3) 0.69 9 (60.0) 17 (43.6) 0.28
Follow up, mean (s.d.) in months 70.5 (32.6) 58.1 (35.9) 0.19 52.3 (33.7) 57.7 (27.4) 0.54
Baseline characteristics and clinicopathological data stratified for low and high MVD for both stage II and III colon cancer. P-values were calculated by chi-square
test or independent t-testing for continuous data
*Significant p-value < 0.05
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added value as a prognostic biomarker in a multivariate
setting.
In addition to MVD, only right-sidedness and ulcer-
ation were retained in stage II colon cancer. For stage III
colon cancer ulceration and angioinvasion in stage III
were retained in the model (Table 2). TSP, HIF1A and
VEGFA were not associated with DFS in this multivariate
assay. No correlations between MVD and TSP or expres-
sion of HIF1A and VEGFA were found. MVD was corre-
lated to expression of VEGFA in stage II colon cancer
(correlation coefficient − 0.331, p = 0.020, Additional file 2:
Table S2).
Discussion
This study addressed the analysis of microvessel density
and its relation to disease stage and prognosis, in micro-
satellite stable stage II and III colon cancer patients.
MVD was higher in stage III compared to stage II colon
cancers. Previously it has been shown that MVD in-
creases during the progression from normal mucosa,
through adenomas to carcinomas [38]. It is plausible
that during the evolution from stage I carcinoma to me-
tastasized disease (stage IV), angiogenesis and MVD are
enhanced to meet the increasing demands of tumour
growth and progression.
In stage II, high MVD was related to worse disease
outcome, i.e. worse DFS, in particular observed as a
significant effect in the multivariate analysis. Thus, stage
II colon cancers with high MVD might represent a
biological subset of cancers with unfavourable character-
istics and a tendency to progression, in line with the
observation mentioned previously, leading to worse
prognosis. A similar trend, albeit not reaching statistical
significance, was found for TSP. All stage III tissues were
obtained from patients who were treated with adjuvant
chemotherapy after resection of their primary tumour.
In contrast to stage II, high MVD was related to im-
proved DFS in stage III patients. Stage III cancers
already proved to have lymphatic potential, and can only
progress to metastasized disease, stage IV. Although the
primary tumours are already resected, residual tumour
tissue, whether located in lymphatic tissue or already as
subclinical distant metastasis, potentially exert the same
tumour characteristics as the primary tumour [39].
Therefore, residual tumour tissue or early recurrent tu-
mours, from primary tumours with high MVD, might
have higher MVD as well and potentially allow better
penetration for the adjuvant 5-FU based chemotherapy.
This might explain the better prognosis of 5-FU treated
stage III colon cancers with high MVD. It seems that
A B
Fig. 3 Kaplan Meier curves for DFS of stage II (a) and stage III (b) colon cancer patients, stratified for high and low MVD. Hazard ratio (HR), 95%
confidence interval, and log-rank p-values are reported
Table 2 Results for multivariate analysis
Stage Parameters HR 95%-CI P-value
II Right-sided tumour 0.18 0.04–0.83 0.027
Ulceration 6.80 0.89–52.23 0.065
High microvessel density 4.50 1.38–14.64 0.013*
III Ulceration 0.32 0.10–1.06 0.062
Angioinvasion 4.38 1.71–11.23 0.002
High microvessel density 0.34 0.13–0.90 0.031*
Multivariate backward Cox-regression analysis for 5-year disease free survival
of high microvessel density and clinicopathological parameters that were
retained in the model, in stage II and III colon cancer patients. HR Hazard ratio,
95%-CI 95% confidence interval
*Significant p-value < 0.05
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even though high-MVD stage III cancers should have
worse prognosis when untreated, they actually might
predict better response to adjuvant chemotherapy. This
hypothesis might also explain why Bevacizumab in stage
II colon cancer does not improve DFS [40]. In stage II,
with already fewer (micro) vessels present, only patients
with high MVD (high risk) might benefit from inhibiting
formation of new vessels. This might explain why there
was no improvement of DFS for the entire group of
stage II patients, since the group with favourable prog-
nosis (low MVD) might show no further improvement
by reduction of the already low vessel density. Potentially
there is benefit from Bevacizumab in lower stages of
colon cancer, though restricted to selected cases with
high MVD.
Tumour-stroma percentage and the expression of
HIF1A and VEGFA, although functionally intercon-
nected, were not significantly associated with MVD in
this study, except for correlation between MVD and
expression of VEGFA in stage II. Interestingly, for the
association of stromal percentage with DFS for stage II
and III, an opposite effect on DFS was observed in both
stages similar as for MVD.
With regards to the method of MVD-analysis, sev-
eral measures were taken to avoid some well-known
methodological difficulties. In literature concerning
MVD in colon cancer, results on prognosis were
ambiguous, possibly for its wide range of methods.
Antibodies used to visualize endothelial cells differ
amongst studies (CD31, CD34, factor VIII, miRNA-
126) [28], and sampling of the measurement area
within the tumour is another critical factor. It is ac-
cepted to define MVD in ‘hot-spots’, but there is no
consensus about the number of hotspots needed to
count [24, 29–31, 41]. Furthermore, ‘hotspot’ may
refer to the invasive margin of the tumour, or the
area in the tumour with highest MVD by ‘eyeballing’.
Both selection methods may be observer-dependent.
Finally, microvessels can be counted manually or digitized
using quantitative image analysis, of which the latter has
proven to have more accuracy and prognostic relevance
[24]. These and other ambiguities may contribute to the
fact that MVD is not unanimously described as a prognos-
tic factor, prohibiting it from being implemented in stand-
ard histopathological examination. To avoid such
observer-dependent area selection, MVD was analysed
digitally and in whole sections in which the entire
tumour-area was annotated. This excluded both the bias
of hot-spot diameter/selection, as the disadvantages of
manual counting. It contributed to a more robust, feasible,
reproducible and observer-independent method. To iden-
tify endothelial cells, CD31 antibodies were used as a com-
monly accepted marker [27], taking into account that it
can be found on platelets and white blood cells to some
degree as well. On the other hand, it is more sensitive for
younger and more immature vessels.
Conclusions
MVD is a surrogate marker of angiogenesis in tumours,
direct measurement of which so far has remained im-
possible. Still, measuring MVD remains subject to some
practical challenges, of which some were tackled in this
study. In the present study, an increased MVD was seen
in stage III colon cancer patients, in comparison to stage
II. MVD appeared to be an independent prognostic fac-
tor associated with poor DFS in stage II colon cancer
patients, and with better DFS in stage III colon cancer
patients who were treated with adjuvant 5-FU based
chemotherapy afterwards. This latter observation may be
of particular clinical interest, pending further validation.
Additional files
Additional file 1: Containing the CD31 specific script for microvessel
density analysis. (DOCX 23 kb)
Additional file 2: Table S1. The clinicopathlogical data stratified for
stage II and III patients. Table S2. The results of the correlation analysis of
MVD, TSP, HIF1a and VEGFa. (DOCX 18 kb)
Additional File 3: Figure S1. DFS stratified for high and low stromal
percentage. Figure S2. DFS stratified for high and low expression of
HIF1A. Figure S3. DFS stratified for high and low expression of VEGFA.
(PPTX 101 kb)
Abbreviations
5-FU: 5-fluorouracil; CI: Confidence interval; DFS: Disease free survival;
FFPE: Formalin-fixed paraffin-embedded; HR: Hazard ratio; MSI: Microsatellite
instability; MSS: Microsatellite stable; MVD: Microvessel density; TMA: Tissue




Study concepts: SU, EB, HB, HS, JB, GM, RF. Study design: SU, EB, OK, JB, GM,
RF. Data acquisition: SU, EvdB, TV, PD, EB. Quality control of data and
algorithms: SU, VC, PD, JB, RF. Data analysis and interpretation: SU, EvdB, VC,
TV, OK, HB, HS, JB, GM, RF. Statistical analysis: SU, VC, RF. Manuscript
preparation: SU, RF, PD, TV, EvdB, JB, GM. Manuscript editing: SU, RF, TV,
EvdB, HS, HB, JB, GM. Manuscript review: All. All authors read and approved
the final manuscript.
Funding
This work was financially supported by the ‘Stichting Chirurg en Onderzoek
Kennemerland’ (Kennemer Gasthuis, Haarlem) and by the VUmc Cancer
Center Amsterdam (project grant CCA 2011-5-06). This work was performed
within the framework of the Center for Translational Molecular Medicine,
DeCoDe project (030–101) and TraIT (05 T-401).
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
Clinical data and tumour tissue was obtained conform the “Code for Proper
Secondary Use of Human Tissue in The Netherlands”34.
Consent for publication
Not applicable.
Uil et al. BMC Gastroenterology          (2019) 19:146 Page 7 of 9
Competing interests
Dr. R.J.A. Fijneman is member of the editorial board (Associate Editor) of
BMC Gastroenterology.Furthermore, the authors declare that they have no
competing interests.
Author details
1Department of Surgery, Spaarne Gasthuis, Boerhaavelaan 22, Haarlem 2035
RC, The Netherlands. 2Department of Pathology and Medical Biology,
University of Groningen, University Medical Center Groningen, Groningen
9700 RB, The Netherlands. 3Department of Epidemiology and Biostatistics, VU
University Medical Center, de Boelelaan 1089a, Amsterdam 1081 HV, The
Netherlands. 4Department of Surgical Oncology, UMC Utrecht Cancer Center,
University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The
Netherlands. 5Department of Pathology, The Netherlands Cancer Institute,
Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands. 6Department of
Pathology, Spaarne Gasthuis, Boerhaavelaan 22, Haarlem 2035 RC, The
Netherlands. 7Department of Surgery, Albert Schweitzer Ziekenhuis,
Dordrecht 3300 AK, The Netherlands. 8Department of Pathology, Amsterdam
University Medical Centre, Vrije Universiteit Amsterdam, de Boelelaan 1117,
Amsterdam 1081 HV, The Netherlands.
Received: 22 May 2019 Accepted: 31 July 2019
References
1. Hanahan D, Weinberg RA. Hallmarks of Cancer: the next generation. Cell.
2011;144(5):646–74.
2. Raica M, Cimpean AM, Ribatti D. Angiogenesis in pre-malignant conditions.
Eur J Cancer. 2009;45(11):1924–34.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–64.
4. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM.
Abnormalities in pericytes on blood vessels and endothelial sprouts in
tumors. Am J Pathol. 2002;160(3):985–1000.
5. Hashizume H, Baluk P, Morikawa S, Mclean JW, Thurston G, Roberge S, et al.
Openings between defective endothelial cells explain tumor vessel
leakiness. Am J Pathol. 2000;156(4):1363–80.
6. Boucher Y, Baxter LT, Jain RK. Interstitial pressure-gradients in Tissue-isolated and
subcutaneous tumors - implications for therapy. Cancer Res. 1990;50(15):4478–84.
7. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO (2) gradients
in solid tumors in vivo: high-resolution measurements reveal a lack of
correlation. Nat Med. 1997;3(2):177–82.
8. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin
Cancer Biol. 2009;19(5):329–37.
9. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev
Cancer. 2003;3(6):401–10.
10. De Palma M, Biziato D, Pingitore R. Microenvironmental regulation of
tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457–74.
11. Clifford RL, Deacon K, Knox AJ. Novel regulation of vascular endothelial
growth factor-a (VEGF-A) by transforming growth factor (beta)1:
requirement for Smads, (beta)-CATENIN, AND GSK3(beta). J Biol Chem. 2008;
283(51):35337–53.
12. Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, et al. Beta-catenin
regulates vascular endothelial growth factor expression in colon cancer.
Cancer Res. 2003;63(12):3145–53.
13. Faviana P, Boldrini L, Spisni R, Berti P, Galleri D, Biondi R, et al.
Neoangiogenesis in colon cancer: correlation between vascular density,
vascular endothelial growth factor (VEGF) and p53 protein expression.
Oncol Rep. 2002;9(3):617–20.
14. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer
GA, et al. Up-regulation of gene expression by hypoxia is mediated
predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol. 2005;
206(3):291–304.
15. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a
new role for the guardian of the genome. J Mol Med. 2007;85(11):1175–86.
16. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial
growth factor gene--a concert of activating factors. Cardiovasc Res. 2005
Feb 15;65(3):564–73.
17. Wincewicz A, Sulkowska M, Koda M, Sulkowski S. Cumulative expression of
HIF-1-alpha, Bax, Bcl-xL and P53 in human colorectal cancer. Pathology.
2007;39(3):334–8.
18. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a
critical cytokine in tumor angiogenesis and a potential target for diagnosis
and therapy. J Clin Oncol. 2002;20(21):4368–80.
19. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour
activity. Nat Rev Cancer. 2008;8(8):579–91.
20. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal Cells in Tumor
Microenvironment and Breast Cancer. Cancer Metastasis Rev. 2013;32(1-2):303-15.
21. Huijbers A, Tollenaar RA, van Pelt GW, Zeestraten EC, Dutton S, McConkey
CC, et al. The proportion of tumor-stroma as a strong prognosticator for
stage II and III colon canver patients: validation in the VICTOR trial. Ann
Oncol. 2013;24(1):179–85.
22. Huijbers A, van Pelt GW, Kerr RS, Johnstone EC, Tollenaar RA, Kerr DJ, et al.
The value of additional bevacizumab in patients with high-risk stroma-high
colon cancer. A study within the QUASAR2 trial, an open-label randomized
phase 3 trial. J Surg Oncol. 2018;117(5):1043–8.
23. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients:
the evidence continues to grow. J Pathol. 1998;184(2):119–22.
24. Hansen TF, Nielsen BS, Jakobsen A, Sorensen FB. Visualising and quantifying
angiogenesis in metastatic colorectal cancer. Cell Oncol. 2013;36(4):341–50.
25. Gasparini G. Clinical significance of determination of surrogate markers of
angiogenesis in breast cancer. Crit Rev Oncol Hematol. 2001;37(2):97–114.
26. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a
prognostic factor in women with breast cancer: a systematic review of the
literature and meta-analysis. Cancer Res. 2004;64(9):2941–55.
27. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM,
et al. The role of microvessel density on the survival of patients with lung
cancer: a systematic review of the literature with meta-analysis. Br J Cancer.
2002 Sep 23;87(7):694–701.
28. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al.
Microvessel density and VEGF expression are prognostic factors in colorectal
cancer. Meta-analysis of the literature. Br J Cancer. 2006;94(12):1823–32.
29. Rajaganeshan R, Prasad R, Guillou PJ, Chalmers CR, Scott N, Sarkar R, et al.
The influence of invasive growth pattern and microvessel density on
prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer.
2007;96(7):1112–7.
30. Wang Y, Yao X, Ge J, Hu F, Zhao Y. Can vascular endothelial growth factor
and microvessel density be used as prognostic biomarkers for colorectal
cancer? A systematic review and meta-analysis. ScientificWorldJournal. 2014;
2014:102736.
31. Goldis DS, Sferdian MF, Tarta C, Fulger LO, Totolici BD, Neamtu C.
Comparative analysis of microvessel density quantified through the
immunohistochemistry expression of CD34 and CD105 in rectal cancer.
Romanian J Morphol Embryol. 2015;56(2):419–24.
32. Zhu B, Zhou L, Yu L, Wu S, Song W, Gong X, et al. Evaluation of the
correlation of vasculogenic mimicry, ALDH1, KAI1 and microvessel density
in the prediction of metastasis and prognosis in colorectal carcinoma. BMC
Surg. 2017;17(1):47.
33. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis
and metastasis--correlation in invasive breast carcinoma. N Engl J
Med. 1991;324(1):1–8.
34. Belt EJT, Fijneman RJA, van den Berg EG, Bril H, Delis-van Diemen PM, Tijssen M,
et al. Loss of Lamin a/C expression in stage II and III Colon Cancer is associated
with disease Recurrenece. Eur J Cancer. 2011;47(12):1837–45.
35. Human Tissue and Medical Research: Code of conduct for responsible
use (2011). 2014.
36. Hadi AM, Mouchaers KT, Schalij I, Grunberg G, Meijer GA, Vonk-Noordegraaf
A, et al. Rapid quantification of myocardial fibrosis: a new macro-based
automated analysis. Cell Oncol. 2010;33(5):257–69.
37. den Uil SH, Coupe VM, Linnekamp JF, van den Broek E, Goos JA, Delis-van
Diemen PM, et al. Loss of KCNQ1 expression in stage II and stage III colon
cancer patients is a strong prognostic factor for disease recurrence. Br J
Cancer. 2016;115(12):1565–74.
38. Bossi P, Viale G, Lee AK, Alfano R, Coggi G, Bosari S. Angiogenesis in
colorectal tumors: microvessel quantitation in adenomas and carcinomas
with clinicopathological correlations. Cancer Res. 2013;55:5049–53.
39. Vignot S, Lefebvre C, Frampton GM, Meurice G, Yelensky R, Palmer G, et al.
Comparative analysis of primary tumour and matched metastases in
colorectal cancer patients: evaluation of concordance between genomic
and transcriptional profiles. Eur J Cancer. 2015;51(7):791–9.
40. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, Wolmark
N. Bevacizumab in stage II-III colon cancer: 5-year update of the National
Uil et al. BMC Gastroenterology          (2019) 19:146 Page 8 of 9
Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;
31(3):359–64.
41. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human
solid tumours. Br J Cancer. 2002;86(10):1566–77.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Uil et al. BMC Gastroenterology          (2019) 19:146 Page 9 of 9
